调强放疗用于宫颈癌根治性治疗:一项Meta分析
该Meta分析纳入6项研究共1008例接受根治性治疗的宫颈癌患者(IMRT组350例,3D-CRT/2D-RT组658例),比较IMRT与3D-CRT或2D-RT的疗效与毒性。结果显示两组3年总生存和无病生存无显著差异,IMRT组急性胃肠道和泌尿生殖道毒性及慢性泌尿生殖道毒性显著降低。
要点
- IMRT与3D-CRT或2D-RT的3年OS和3年DFS无显著差异。
- IMRT组急性胃肠道和泌尿生殖道毒性发生率显著低于对照组。
- IMRT组慢性泌尿生殖道3级毒性发生率显著低于对照组。
核心结论
- IMRT与传统放疗在3年OS和DFS方面疗效相当,且IMRT显著降低宫颈癌患者急性胃肠道和泌尿生殖道毒性及慢性泌尿生殖道毒性。
研究设计与样本
- Meta分析,检索PubMed、Cochrane Library、Web of Science和Elsevier数据库,纳入6项研究共1008例接受根治性治疗的宫颈癌患者(IMRT组350例,3D-CRT/2D-RT组658例),使用RevMan 5.2软件分析。
主要发现
- IMRT组与3D-CRT或2D-RT组比较,3年OS的OR=2.41(95%CI 0.62-9.39,p=0.21),3年DFS的OR=1.44(95%CI 0.69-3.01,p=0.33),均无显著差异。
- IMRT组急性胃肠道2级毒性OR=0.5(95%CI 0.28-0.89,p=0.02),3级或以上OR=0.55(95%CI 0.32-0.95,p=0.03),均显著低于对照组。
- IMRT组急性泌尿生殖道2级毒性OR=0.41(95%CI 0.2-0.84,p=0.01),3级或以上OR=0.31(95%CI 0.14-0.67,p=0.003),均显著低于对照组。
- IMRT组慢性泌尿生殖道3级毒性OR=0.09(95%CI 0.01-0.67,p=0.02),显著低于对照组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the efficacies and toxicities of intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3D-CRT) or conventional two-dimensional radiotherapy (2D-RT) for definitive treatment of cervical cancer. METHODS: A meta-analysis was performed using search engines, including PubMed, Cochrane Library, Web of Science, and Elsevier. In the meta-analysis, odds ratios (ORs) were compared for overall survival (OS), disease-free survival (DFS), and acute and chronic toxicities. RESULTS: Included data were analysed using RevMan 5.2 software. Six studies encompassing a total of 1008 patients who received definitive treatment (IMRT = 350, 3-DCRT/2D-RT = 658) were included in the analysis. A comparison of 3-year OS and 3-year DFS revealed no significant differences between IMRT and 3D-CRT or 2D-RT (3-year OS: OR = 2.41, 95% confidence interval [CI]: 0.62-9.39, p = 0.21; 3-year DFS: OR = 1.44, 95% CI: 0.69-3.01, p = 0.33). The incidence of acute gastrointestinal (GI) toxicity and genitourinary (GU) toxicity in patients who received IMRT was significantly lower than that in the control group (GI: Grade 2: OR = 0.5, 95% CI: 0.28-0.89, p = 0.02; Grade 3 or higher: OR = 0.55, 95% CI: 0.32-0.95, p = 0.03; GU: Grade 2: OR = 0.41, 95% CI: 0.2-0.84; p = 0.01; Grade 3 or higher: OR = 0.31, 95% CI: 0.14-0.67, p = 0.003). Moreover, the IMRT patients experienced fewer incidences of chronic GU toxicity than did the control group (Grade 3: OR = 0.09, 95% CI: 0.01-0.67, p = 0.02). CONCLUSION: IMRT and conventional radiotherapy demonstrated equivalent efficacy in terms of 3-year OS and DFS. Additionally, IMRT significantly reduced acute GI and GU toxicities as well as chronic GU toxicity in patients with cervical cancer.
引用
- Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol. 2018. PMID: 30217165. doi:10.1186/s13014-018-1126-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。